In addition, multiple clinical studies in medullary thyroid carcinoma, melanoma, breast, ovarian, and prostate cancer have shown a direct correlation between serum CXCL8/IL-8 levels and disease progression [65, 66]. The gene discussed is CXCL8; the disease is prostate carcinoma.